Skip to main content
Top
Published in: Respiratory Research 1/2011

Open Access 01-12-2011 | Research

Pseudomonas aeruginosa toxin ExoU induces a PAF-dependent impairment of alveolar fibrin turnover secondary to enhanced activation of coagulation and increased expression of plasminogen activator inhibitor-1 in the course of mice pneumosepsis

Authors: Gloria-Beatriz Machado, Albanita V de Oliveira, Alessandra M Saliba, Carolina D Mallet de Lima, José HR Suassuna, Maria-Cristina Plotkowski

Published in: Respiratory Research | Issue 1/2011

Login to get access

Abstract

Background

ExoU, a Pseudomonas aeruginosa cytotoxin with phospholipase A2 activity, was shown to induce vascular hyperpermeability and thrombus formation in a murine model of pneumosepsis. In this study, we investigated the toxin ability to induce alterations in pulmonary fibrinolysis and the contribution of the platelet activating factor (PAF) in the ExoU-induced overexpression of plasminogen activator inhibitor-1 (PAI-1).

Methods

Mice were intratracheally instilled with the ExoU producing PA103 P. aeruginosa or its mutant with deletion of the exoU gene. After 24 h, animal bronchoalveolar lavage fluids (BALF) were analyzed and lung sections were submitted to fibrin and PAI-1 immunohistochemical localization. Supernatants from A549 airway epithelial cells and THP-1 macrophage cultures infected with both bacterial strains were also analyzed at 24 h post-infection.

Results

In PA103-infected mice, but not in control animals or in mice infected with the bacterial mutant, extensive fibrin deposition was detected in lung parenchyma and microvasculature whereas mice BALF exhibited elevated tissue factor-dependent procoagulant activity and PAI-1 concentration. ExoU-triggered PAI-1 overexpression was confirmed by immunohistochemistry. In in vitro assays, PA103-infected A549 cells exhibited overexpression of PAI-1 mRNA. Increased concentration of PAI-1 protein was detected in both A549 and THP-1 culture supernatants. Mice treatment with a PAF antagonist prior to PA103 infection reduced significantly PAI-1 concentrations in mice BALF. Similarly, A549 cell treatment with an antibody against PAF receptor significantly reduced PAI-1 mRNA expression and PAI-1 concentrations in cell supernatants, respectively.

Conclusion

ExoU was shown to induce disturbed fibrin turnover, secondary to enhanced procoagulant and antifibrinolytic activity during P. aeruginosa pneumosepsis, by a PAF-dependent mechanism. Besides its possible pathophysiological relevance, in vitro detection of exoU gene in bacterial clinical isolates warrants investigation as a predictor of outcome of patients with P. aeruginosa pneumonia/sepsis and as a marker to guide treatment strategies.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Schultz MJ, Levi M: Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury. Thorax. 2000, 62: 563-564.CrossRef Schultz MJ, Levi M: Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury. Thorax. 2000, 62: 563-564.CrossRef
3.
go back to reference Seeger W, Hübel J, Klapettek K, Pison U, Obertacke U, Joka T, Roka L: Procoagulant activity in bronchoalveolar lavage of severely traumatized patients - relation to the development of acute respiratory distress. Thromb Res. 1991, 61: 53-64.CrossRefPubMed Seeger W, Hübel J, Klapettek K, Pison U, Obertacke U, Joka T, Roka L: Procoagulant activity in bronchoalveolar lavage of severely traumatized patients - relation to the development of acute respiratory distress. Thromb Res. 1991, 61: 53-64.CrossRefPubMed
4.
go back to reference Levi M, van der Poll T: Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005, 15: 254-259. 10.1016/j.tcm.2005.07.004.CrossRefPubMed Levi M, van der Poll T: Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005, 15: 254-259. 10.1016/j.tcm.2005.07.004.CrossRefPubMed
5.
go back to reference Prabhakaran P, Ware L, White K, Cross M, Matthay M, Olman M: Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003, 285: L20-L28.CrossRefPubMed Prabhakaran P, Ware L, White K, Cross M, Matthay M, Olman M: Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003, 285: L20-L28.CrossRefPubMed
6.
go back to reference Scheetz MH, Pharm D, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, Sriram P, Dinh M, Owens LK, Hauser AR: Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis. 2009, 64: 311-319. 10.1016/j.diagmicrobio.2009.02.006.CrossRefPubMedPubMedCentral Scheetz MH, Pharm D, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, Sriram P, Dinh M, Owens LK, Hauser AR: Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis. 2009, 64: 311-319. 10.1016/j.diagmicrobio.2009.02.006.CrossRefPubMedPubMedCentral
7.
go back to reference Sato H, Frank DW: ExoU is a potent intracellular phospholipase. Mol Microbiol. 2004, 53: 1279-1290. 10.1111/j.1365-2958.2004.04194.x.CrossRefPubMed Sato H, Frank DW: ExoU is a potent intracellular phospholipase. Mol Microbiol. 2004, 53: 1279-1290. 10.1111/j.1365-2958.2004.04194.x.CrossRefPubMed
8.
go back to reference Feltman HG, Schulert G, Khan S, Jain M, Peterson L, Hauser AR: Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001, 147: 2659-2669.CrossRefPubMed Feltman HG, Schulert G, Khan S, Jain M, Peterson L, Hauser AR: Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001, 147: 2659-2669.CrossRefPubMed
9.
go back to reference Hurley BP, McCormick BA: Multiple roles of phospholipase A2 during lung infection and inflammation. Infect Immun. 2008, 76: 2259-2272. 10.1128/IAI.00059-08.CrossRefPubMedPubMedCentral Hurley BP, McCormick BA: Multiple roles of phospholipase A2 during lung infection and inflammation. Infect Immun. 2008, 76: 2259-2272. 10.1128/IAI.00059-08.CrossRefPubMedPubMedCentral
10.
go back to reference Yost CC, Weyrich AS, Zimmerman GA: The platelet Activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie. 2010, 92: 692-697. 10.1016/j.biochi.2010.02.011.CrossRefPubMedPubMedCentral Yost CC, Weyrich AS, Zimmerman GA: The platelet Activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie. 2010, 92: 692-697. 10.1016/j.biochi.2010.02.011.CrossRefPubMedPubMedCentral
11.
go back to reference Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002, 30: S294-301. 10.1097/00003246-200205001-00020.CrossRefPubMed Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002, 30: S294-301. 10.1097/00003246-200205001-00020.CrossRefPubMed
12.
go back to reference Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R: Platelet-activating factor in experimental and clinical sepsis. Shock. 1997, 7: 391-404. 10.1097/00024382-199706000-00001.CrossRefPubMed Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R: Platelet-activating factor in experimental and clinical sepsis. Shock. 1997, 7: 391-404. 10.1097/00024382-199706000-00001.CrossRefPubMed
13.
go back to reference Touqui L, Hatmi M, Vargaftig BB: Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. Biochem J. 1985, 229: 811-6.CrossRefPubMedPubMedCentral Touqui L, Hatmi M, Vargaftig BB: Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. Biochem J. 1985, 229: 811-6.CrossRefPubMedPubMedCentral
14.
go back to reference Howard KM, Miller JE, Miwa M, Olson MS: Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem. 1997, 272: 27543-27548. 10.1074/jbc.272.44.27543.CrossRefPubMed Howard KM, Miller JE, Miwa M, Olson MS: Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem. 1997, 272: 27543-27548. 10.1074/jbc.272.44.27543.CrossRefPubMed
15.
go back to reference Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM: Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem. 1998, 273: 4012-4020. 10.1074/jbc.273.7.4012.CrossRefPubMed Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM: Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem. 1998, 273: 4012-4020. 10.1074/jbc.273.7.4012.CrossRefPubMed
16.
go back to reference Saliba AM, Nascimento DO, Silva MC, Assis MC, Gayer CR, Raymond B, Coelho MG, Marques EA, Touqui L, Albano RM, Lopes UG, Paiva DD, Bozza PT, Plotkowski MC: Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol. 2005, 7: 1811-1822. 10.1111/j.1462-5822.2005.00635.x.CrossRefPubMed Saliba AM, Nascimento DO, Silva MC, Assis MC, Gayer CR, Raymond B, Coelho MG, Marques EA, Touqui L, Albano RM, Lopes UG, Paiva DD, Bozza PT, Plotkowski MC: Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol. 2005, 7: 1811-1822. 10.1111/j.1462-5822.2005.00635.x.CrossRefPubMed
17.
go back to reference Plotkowski MC, Brandão BA, Assis MC, Feliciano LFP, Saliba AM, Raymond B, Marques EA, Zahm JM, Touqui L, Bozza PT: Lipid body mobilization in the ExoU-induced release of inflammatory mediators by airway epithelial. Microbial Pathogenesis. 2008, 45: 30-37. 10.1016/j.micpath.2008.01.008.CrossRefPubMed Plotkowski MC, Brandão BA, Assis MC, Feliciano LFP, Saliba AM, Raymond B, Marques EA, Zahm JM, Touqui L, Bozza PT: Lipid body mobilization in the ExoU-induced release of inflammatory mediators by airway epithelial. Microbial Pathogenesis. 2008, 45: 30-37. 10.1016/j.micpath.2008.01.008.CrossRefPubMed
18.
go back to reference Plotkowski MC, Feliciano LF, Machado GB, Cunha LG, Freitas C, Saliba AM, de Assis MC: ExoU-induced procoagulant activity in Pseudomonas aeruginosa-infected airway cells. Eur Respir J. 2008, 32: 1591-1598. 10.1183/09031936.00086708.CrossRefPubMed Plotkowski MC, Feliciano LF, Machado GB, Cunha LG, Freitas C, Saliba AM, de Assis MC: ExoU-induced procoagulant activity in Pseudomonas aeruginosa-infected airway cells. Eur Respir J. 2008, 32: 1591-1598. 10.1183/09031936.00086708.CrossRefPubMed
19.
go back to reference Machado GB, de Assis MC, Leão R, Saliba AM, Silva MC, Suassuna JH, de Oliveira AV, Plotkowski MC: ExoU-induced vascular hyperpermeability and platelet activation in the course of experimental Pseudomonas aeruginosa pneumosepsis. Shock. 2010, 33: 315-321. 10.1097/SHK.0b013e3181b2b0f4.CrossRefPubMed Machado GB, de Assis MC, Leão R, Saliba AM, Silva MC, Suassuna JH, de Oliveira AV, Plotkowski MC: ExoU-induced vascular hyperpermeability and platelet activation in the course of experimental Pseudomonas aeruginosa pneumosepsis. Shock. 2010, 33: 315-321. 10.1097/SHK.0b013e3181b2b0f4.CrossRefPubMed
20.
go back to reference Ottino P, Taheri F, Bazan HE: Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: imbalance between the gene expression of MMP-9 and TIMP-1 and -2. Exp Eye Res. 2002, 74: 393-402. 10.1006/exer.2001.1135.CrossRefPubMed Ottino P, Taheri F, Bazan HE: Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: imbalance between the gene expression of MMP-9 and TIMP-1 and -2. Exp Eye Res. 2002, 74: 393-402. 10.1006/exer.2001.1135.CrossRefPubMed
21.
go back to reference Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980, 26: 171-176. 10.1002/ijc.2910260208.CrossRefPubMed Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980, 26: 171-176. 10.1002/ijc.2910260208.CrossRefPubMed
22.
go back to reference Howard KM, Abdel-Al M, Ditmyer M, Patel N: Lipopolysaccharide and platelet-activating factor stimulate expression of platelet-activating factor acetylhydrolase via distinct signaling pathways. Inflamm Res. 2011, 60: 735-744. 10.1007/s00011-011-0326-5.CrossRefPubMedPubMedCentral Howard KM, Abdel-Al M, Ditmyer M, Patel N: Lipopolysaccharide and platelet-activating factor stimulate expression of platelet-activating factor acetylhydrolase via distinct signaling pathways. Inflamm Res. 2011, 60: 735-744. 10.1007/s00011-011-0326-5.CrossRefPubMedPubMedCentral
23.
go back to reference Schulert GS, Feltman H, Rabin SDP, Martin CG, Battle SE, Rello J, Hauser AR: Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis. 2003, 188: 1695-1706. 10.1086/379372.CrossRefPubMed Schulert GS, Feltman H, Rabin SDP, Martin CG, Battle SE, Rello J, Hauser AR: Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis. 2003, 188: 1695-1706. 10.1086/379372.CrossRefPubMed
24.
go back to reference Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest. 1989, 84: 695-705. 10.1172/JCI114217.CrossRefPubMedPubMedCentral Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest. 1989, 84: 695-705. 10.1172/JCI114217.CrossRefPubMedPubMedCentral
25.
go back to reference Bastarache JA, Wang L, Geiser T, Wang Z, Albertine KH, Matthay MA, Ware LB: The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax. 2007, 62: 608-616. 10.1136/thx.2006.063305.CrossRefPubMedPubMedCentral Bastarache JA, Wang L, Geiser T, Wang Z, Albertine KH, Matthay MA, Ware LB: The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax. 2007, 62: 608-616. 10.1136/thx.2006.063305.CrossRefPubMedPubMedCentral
26.
go back to reference Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB: Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L874-L881. 10.1152/ajplung.00372.2007.CrossRefPubMedPubMedCentral Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB: Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L874-L881. 10.1152/ajplung.00372.2007.CrossRefPubMedPubMedCentral
27.
go back to reference Higuchi DA, Wun TC, Likert KM, Broze GJ: The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood. 1992, 79: 1712-1719.PubMed Higuchi DA, Wun TC, Likert KM, Broze GJ: The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood. 1992, 79: 1712-1719.PubMed
28.
go back to reference Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD: Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem. 2000, 275: 27123-128.PubMed Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD: Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem. 2000, 275: 27123-128.PubMed
29.
go back to reference Gando S, Kameue T, Matsuda N, Hayakawa M, Morimoto Y, Ishitani T, Kemmotsu O: Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res. 2003, 109: 119-124. 10.1016/S0049-3848(03)00151-8.CrossRefPubMed Gando S, Kameue T, Matsuda N, Hayakawa M, Morimoto Y, Ishitani T, Kemmotsu O: Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res. 2003, 109: 119-124. 10.1016/S0049-3848(03)00151-8.CrossRefPubMed
30.
go back to reference Günther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbrück B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000, 161: 454-462.CrossRefPubMed Günther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbrück B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000, 161: 454-462.CrossRefPubMed
31.
go back to reference Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S: The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling and cellular viability. Am J Physiol Lung Cell Mol Physiol. 2008, 295: L967-975. 10.1152/ajplung.90349.2008.CrossRefPubMed Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S: The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling and cellular viability. Am J Physiol Lung Cell Mol Physiol. 2008, 295: L967-975. 10.1152/ajplung.90349.2008.CrossRefPubMed
32.
go back to reference Srinivasan R, Song Y, Wiener-Kronish J, Flori HR: Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients. Pediatr Crit Care Med. 2011, 12: 21-27. 10.1097/PCC.0b013e3181e2a352.CrossRefPubMed Srinivasan R, Song Y, Wiener-Kronish J, Flori HR: Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients. Pediatr Crit Care Med. 2011, 12: 21-27. 10.1097/PCC.0b013e3181e2a352.CrossRefPubMed
33.
go back to reference Song Y, Wiener-Kronish JP, Flanagan J, Lynch SV: Alveolar hemostasis in patients with species-specific bacterial-mediated ventilator-associated pneumonia. Crit Care Med. 2007, 35: 652-653. 10.1097/01.CCM.0000254050.98225.6B.CrossRefPubMed Song Y, Wiener-Kronish JP, Flanagan J, Lynch SV: Alveolar hemostasis in patients with species-specific bacterial-mediated ventilator-associated pneumonia. Crit Care Med. 2007, 35: 652-653. 10.1097/01.CCM.0000254050.98225.6B.CrossRefPubMed
34.
go back to reference Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME: Phospholipases A2 and platelet-activating factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med. 2005, 33: 772-779. 10.1097/01.CCM.0000158519.80090.74.CrossRefPubMed Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME: Phospholipases A2 and platelet-activating factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med. 2005, 33: 772-779. 10.1097/01.CCM.0000158519.80090.74.CrossRefPubMed
35.
go back to reference Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, van der Poll T: Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008, 180: 3478-3484.CrossRefPubMed Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, van der Poll T: Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008, 180: 3478-3484.CrossRefPubMed
36.
go back to reference Levitt JE, Gould MK, Ware LB, Matthay MA: The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med. 2009, 24: 151-167. 10.1177/0885066609332603.CrossRefPubMed Levitt JE, Gould MK, Ware LB, Matthay MA: The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med. 2009, 24: 151-167. 10.1177/0885066609332603.CrossRefPubMed
Metadata
Title
Pseudomonas aeruginosa toxin ExoU induces a PAF-dependent impairment of alveolar fibrin turnover secondary to enhanced activation of coagulation and increased expression of plasminogen activator inhibitor-1 in the course of mice pneumosepsis
Authors
Gloria-Beatriz Machado
Albanita V de Oliveira
Alessandra M Saliba
Carolina D Mallet de Lima
José HR Suassuna
Maria-Cristina Plotkowski
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2011
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-12-104

Other articles of this Issue 1/2011

Respiratory Research 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine